Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Alert Sacituzumab Govitecan Gains First-Line TNBC Indications Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 inhibitor ...
Jennifer Simonson is a business journalist with a decade of experience covering entrepreneurship and small business. Drawing on her background as a founder of multiple startups, she writes for Forbes ...
If you don't use your credit card, your issuer may consider your account inactive and close it. However, a closed credit card account can negatively impact your credit score, by increasing your credit ...
SHAREit is a popular application that allows you to easily transfer photos, videos, and files between iPhone, Android, and a Windows PC or Mac without an Internet connection. 2] Using Hotspot. The ...
ASCO 2026 Pivotal Updates in Metastatic Breast Cancer From ASCO 2026 Updates in metastatic breast cancer from ASCO 2026 include PANKU-Breast02 on iza-bren for TNBC, VIKTORIA-1 gedatolisib triplet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results